SAWAI GROUP HOLDINGS Co., Ltd. ( (JP:4887) ) has provided an announcement.
Sawai Group Holdings Co., Ltd. has announced the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd., making it a subsidiary. This strategic move is intended to enhance Sawai’s digital healthcare offerings by integrating FrontAct’s expertise in biosignal processing and disease prediction, thereby strengthening its business foundation and expanding its healthcare solutions beyond traditional drug therapies.
More about SAWAI GROUP HOLDINGS Co., Ltd.
Sawai Group Holdings Co., Ltd. operates in the pharmaceutical industry, primarily focusing on generic drugs. The company is expanding into digital healthcare, aiming to leverage innovative technologies for sustainable growth.
YTD Price Performance: -2.37%
Average Trading Volume: 669,187
Technical Sentiment Signal: Sell
Current Market Cap: Yen242.5B
For detailed information about 4887 stock, go to TipRanks’ Stock Analysis page.